Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-08-08 00:00:00 ET · period of report 2022-08-04 · accession 0001883850-22-000054 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-08-08 | 2022-08-04 | REGN | RYAN ARTHUR F | Dir | S - Sale+OE | $621.29 | -10.5K | 18.4K | -36% | -$6.49M |
| DM | 2022-08-08 | 2022-08-04 | REGN | RYAN ARTHUR F | Dir | M - OptEx | $413.26 | +10.5K | 23.3K | +81% | +$4.32M |
| D | 2022-08-08 | 2022-08-04 | REGN | RYAN ARTHUR F | Dir | G - Gift | $0.00 | -2,500 | 19.7K | -11% | $0 |
| DM | 2022-08-08 | 2022-08-04 | REGN | RYAN ARTHUR F | Dir | M - OptEx | $0.00 | -10.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-04 | S | D | 1,410 | $622.06 | 19,682 | D | — | — | (F3) Represents volume-weighted average price of sales of 1,410 shares of Company stock on August 4, 2022 at prices ranging from $622.00 to $622.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2022 at each separate price. |
| 2 | Common | Common Stock | 2022-08-04 | M | A | 2,479 | $380.95 | 21,092 | D | — | — | |
| 3 | Common | Common Stock | 2022-08-04 | S | D | 4,156 | $621.54 | 18,613 | D | — | — | (F2) Represents volume-weighted average price of sales of 4,156 shares of Company stock on August 4, 2022 at prices ranging from $621.00 to $621.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2022 at each separate price. |
| 4 | Common | Common Stock | 2022-08-04 | M | A | 4,361 | $374.12 | 22,769 | D | — | — | |
| 5 | Common | Common Stock | 2022-08-04 | S | D | 4,887 | $620.85 | 18,408 | D | — | — | (F1) Represents volume-weighted average price of sales of 4,887 shares of Company stock on August 4, 2022 at prices ranging from $620.16 to $620.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2022 at each separate price. |
| 6 | Common | Common Stock | 2022-08-04 | M | A | 3,613 | $482.68 | 23,295 | D | — | — | |
| 7 | Common | Common Stock | 2022-08-04 | G | D | 2,500 | $0.00 | 19,682 | D | — | — | |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-08-04 | M | D | 4,361 | $0.00 | 0 | D | $374.12 · — to 2030-01-02 | 4,361 Common Stock | (F4) On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-08-04 | M | D | 2,479 | $0.00 | 0 | D | $380.95 · — to 2028-01-02 | 2,479 Common Stock | (F5) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
| 10 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-08-04 | M | D | 3,613 | $0.00 | 0 | D | $482.68 · — to 2031-01-04 | 3,613 Common Stock | (F4) On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |